Biogen Idec Ma Inc.

Clariant Finance (bvi) Limited

Biogen Ma Inc.

Graham K Farrington

Alexey Alexandrovich Lugovskoy

Werner Meier

Jeffrey L Browning

Ellen A Garber

Scott Glaser

Christilyn Graff

Diane P Williams

Veronique Bailly

Xinzhong Wang

William Sisk

John K Eldredge

Moreland David Gibbs

Evan Beckman

Paige Anderson

Roy Daniels

Hugh Morgan

Peter Bergquist

The invention is based, at least in part, on the finding that a dimeric version of a BBB-transmigrating antibody (e.g., the TMEM30A (CDC-50A) binding antibody, FC5) was found to greatly enhance transport across the BBB as compared to monovalent FC5 V. The invention provides, inter alia, molecules that increase transport of pharmacologically active agents across the blood brain barrier, methods for increasing transport across the blood brain barrier, and methods of treatment of disorders or diseases having a neurological component.

Enhancement of transport of therapeutic molecules across the blood brain barrier

LIGHT-targeting molecules (e.g., LIGHT fusion molecules), anti-HER2 antibody molecules, compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided.

Light targeting molecules and uses thereof

The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.

Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto

This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof.

Compositions comprising variant LT-B-R-IG fusion proteins

Alkalophilic and thermophilic cellulases having high stability to elevated temperatures and pH have been isolated from an organism of unknown species, which most closely resembles those in the Caldicellulosiruptor genus and which has been called by us, Tok7B.1, These cellulases have been cloned and expressed in a recombinant system, so that they can be produced in quantity. These are particularly useful in treating cellulosic materials including cotton-containing fabrics, as detergent additives, and in aqueous compositions. We also provide genomic DNA which can be used in recombinant expression vectors and expression systems to produce enhanced alkali and/or temperature stability properties in cellulases other than those specifically described.

Compositions and methods for treating cellulose containing fabrics using truncated cellulase enzyme compositions

Growing community of inventors

Acton, MA, United States of America

Graham K Farrington